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Abstract
Problems with antibiotic resistant bacteria are increasing in the
hospital and particularly in the intensive care unit. Methicillin-
resistant  Staphylococcus aureus,  Acinetobacter baumanii and
extended spectrum beta-lactamase producing Gram-negative bacilli
constitute a therapeutic and infection control challenge. Early
enteral feeding improves survival in patients in the intensive care
unit. Prokinetic agents are routinely used in patients with inappro-
priate gastrointestinal motility. The use of erythromycin at sub-
therapeutic doses as a prokinetic agent is a cause of concern for
the following reasons: it can increase the emergence and spread of
antibiotic resistance and the likelihood of Clostridium difficile
disease. The use of an antibiotic as a prokinetic agent does not
constitute prudent antimicrobial prescribing and should be avoided.
Alternative agents, whenever possible, should be used.
There are increasing problems with antimicrobial resistant
bacteria in intensive care. Some examples include Clostridium
difficile, methicillin-resistant Staphylococcus aureus (MRSA),
extended spectrum beta-lactamase producing Gram-negative
bacilli and Acinetobacter baumanii. There is overwhelming
evidence that the use of antibiotics is a driving factor for the
emergence of resistance [1]. This problem is particularly
severe in intensive care areas where antibiotic use is high.
Does the current practice of prescribing of erythromycin for
prokinesis constitute prudent use of antimicrobials [2]?
The mechanisms by which antibiotic use can increase
antibiotic resistance have been reviewed by Lipsitch and
Samore [3] and include: selecting in favour of resistant
strains; creating colonization opportunities for resistant
strains (assuming competition between resistant and
susceptible strains); and encouraging an increased
colonisation ‘load’. In addition, antibiotic use can more rarely
select in favour of the emergence of de novo resistance.
The predominant MRSA strains in the UK are resistant to
erythromycin. We recently conducted an observational
carriage study that supported the view that MRSA and
methicillin-susceptible  S. aureus strains compete for
colonisation space in the anterior nares [4]. Thus, exposure to
macrolides has the potential to alter the composition of the
resident bacterial microbiota in the anterior nares, leading to
selection of MRSA. In support of this, treatment with slow
release clarithromycin has been shown to eliminate nasal
carriage of S. aureus [5]. This would leave patients more
susceptible to colonisation and infection with MRSA.
Berg and co-workers [5] also showed that treatment with a
macrolide increased macrolide resistance in the oro-
pharyngeal flora. This effect was still present at an eight
weeks follow up.
Erythromycin as a prokinetic agent is used at sub-therapeutic
doses, which particularly promotes selection of mutational
resistance [1,6].
Hospitals in North America and Europe are experiencing a
rise in C. difficile infections in the inpatient population caused
by a strain (NAP1/027) that is characterized by increased
toxin production [7]. C. difficile strains isolated from UK
hospitals are resistant to several antibiotics, including
erythromycin [8]. In addition, the transfer of erythromycin
resistance to sensitive C. difficile strains has been linked to
simultaneous acquisition of a gene homologous to C. difficile
toxin A in nontoxigenic strains of C. difficile (9).
Early enteral feeding improves outcome in critically ill patients
by increasing gut blood flow and gut function, improving
wound healing and reducing septic complications. Early
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nutrient intake (within 24 to 48 hours of admission) is now
recommended [10]. Inappropriate gastrointestinal motility
may cause macro- or micro-aspiration of the gastric contents
into the lower respiratory tract, which may act as a risk factor
for ventilator-associated pneumonia. Motility agents are
routinely prescribed in patients with high gastric content,
identified by high volume of fluids aspirated from the
nasogastric tube [11]. The prokinetic agents available have
been reviewed [12], although a subsequent commentary
highlighted the lack of any large methodological studies on
which to base treatment recommendations [10]. In addition,
there is little evidence from clinical trials that erythromycin
used as a prokinetic agent improves the outcome of patients
in intensive care.
Although benefits of early enteral nutrition are evident, there
is lack of evidence to support the use of erythromycin. Other
prokinetic agents like metoclopramide are available, and new
agents are under investigation [13]. Metoclopramide is
recommended by the Canadian Critical Care Society [11].
Prudent use of antibiotics is an essential component of any
strategy aimed at reducing the spread of antimicrobial
resistance and health care associated infections [14].
The use of sub-inhibitory concentrations of erythromycin as a
prokinetic agent contributes to the antibiotic burden, is likely
to lead to the spread of antimicrobial resistance in the
intensive care unit and may increase the likelihood of C.
difficile-associated disease.
This practice is incompatible with the principle of ‘prudent
antimicrobial prescribing’ and should be reserved only for
patients in whom alternative agents are contraindicated.
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